-. % : PDN (PDN). Index case.. : ( ) mg Visual analogue scale (VAS)... : - % %. (). (QOL).. safe : - E-mail: Hamidnoshad1@yahoo.com : :.() ) ( ). ( C-fibers.() modified () - - - 6-7 -
() () () ().().().() ().() (). mg.. visual analogue scale (VAS). -... PTH KT/V. 5HT. PDN HIV () (%) %. (HD) - mg..() mg.().(). (%). / / VAS. VAS score.
- mg. VAS excoriation...() PDN.() PDN. (QOL) HIV.() (%) mg.( mg). (%)..() % ( ).() FDA. Partial (GABA) -.
().() mg.(). VAS. References:. VAS 1. Schwartz IF, Iaina A. Uraemic pruritus. Nephrol Dial Transplant 1999; 14: 834-9. 2. Twycross R, Greaves MW, Handwerker H, Jones EA, Libretto SE, Szepietowski JC. Itch: scratching more than the surface. Q J Med 2003; 96: 7-26. 3. Pauli-Magnus C, Mikus G, Alscher DM, Kirschner T, Nagel W, Gugeler N, et al. Naltrexone does not relieve uremic pruritus: results of a randomised, double blind, placebocontrolled crossover study. J Am Soc Nephrol 2000; 11: 514-9. 4. Zucker I, Yosipovitch G, David M, Gafter U, Boner G. Prevalence and characterization of uremic pruritus in patients undergoing hemodialysis: uremic pruritus is still a major problem for patients with end-stage renal disease. J Am Acad Dermatol 2003; 49: 842-6. 5. Gilchrest BA, Rowe JW, Brown RS, Steinman TI, Arndt KA. Ultraviolet phototherapy of uremic pruritus: long term results and possible mechanisms of action. Ann Intern Med 1979; 91: 17-21. 6. Mettang T, Pauli-Magnus C, Alscher DM. Uraemic pruritus-new perspectives and insights. C-fibers.(). ( ) (mediator)..()..() from recent trials. Nephrol Dial Transplant 2002; 17: 1558-63. 7. Kuypers DR, Claes K, Evenepoel P, Maes B, Vanrenterghem Y. A prospective proof of concept study of the efficacy of tacrolimus ointment on uraemic pruritus (UP) in patients on chronic dialysis therapy. Nephrol Dial Transplant 2004; 19: 1895-901. 8. Silva SR, Viana PC, Lugon NV, Hoette M, Ruzany F, Lugon JR. Thalidomide for the treatment of uremic pruritus: a cross over randomised trial. Nephron 1994; 67: 270-3. 9. Weisshaar E, Dunker N, Rohl FW, Gollnick H. Antipruritic effects of two different 5 HT3 receptor antagonists and an antihistamine in hemodialysis patients. Exp Dermatol 2004; 13: 298-304. 10. Nicholson B. Gabapentin use in neuropathic pain syndromes. Acta Neurol Scand 2000; 101: 359-71. 11. Tremont-Lukats IW, Megeff C, Backonja MM. Anticonvulsants for neuropathic pain syndromes. J Drugs 2000; 60: 1029-52 12. Comstock TJ, Sica DA, Bockbrader HN, Underwood BA, Sedman AJ. Gabapentin
- pharmacokinetics in patients with various degrees of renal function. J Clin Pharmacol 1990; 30: 862. 13. Bassilios N, Launay-Vacher V, Khoury N, Rondeau E, Deray G, Sraer JD. Gabapentin neurotoxicity in a chronic haemodialysis patient. Nephrol Dial Transplant 2001; 16: 2112-3. 14. Thorp ML, Morris CD, Bagby SP. A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients. Am J Kidney Dis 2001; 38: 104-8. 15. Taylor CP, Gee NS, Su TZ, Kocsis JD, Welty DF, Brown JP, et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998; 29: 233-49. 16. Yosipovitch G, Greaves MW, Schmeltz M. Itch. Lancet 2003; 361: 690-4. 17. Ikoma A, Rukwied R, Stander S, Steinhoff M, Miyachi Y, Schmeltz M. Neurophysiology of pruritus. Arch Dermatol 2003; 1475-8. 18. Zakrzewska-Pniewska B, Jedras M. Is pruritus in chronic uremic patients related to peripheral somatic and autonomic neuropathy? Neurophysiol Clin 2001; 31: 181-93. 19. Togashi Y, Umeuchi H, Okano K, Ando N, Honda T, Kawamura K, et al. Antipruritic activity of the kappa-opioid receptor agonist, TRK-820. Eur J Pharmacol 2002; 435: 259-64. 20. Fishman SM, Caneris OA, Stojanovic MP, Borsook D. Intravenous lidocaine for treatmentresistant pruritus. Am J Med 1997; 102: 584-5. 21. Bueller HA, Bernhard JD, Dubroff LM. Gabapentin treatment for brachioradial pruritus. J Eur Acad Dermatol Venereol 1999; 13: 227-8. 22. Winhoven SM, Coulson IH, Bottomley WW. Brachio-radial pruritus: response to treatment with gabapentin. Br J Dermatol 2004; 150: 786-7. 23. Scheinfeld N. The role of gabapentin in treating diseases with cutaneous manifestations and pain. Int J Dermatol 2003; 42: 491-5.